Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Glioblastoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 4Temozolomide 3Radiotherapy 2vocimagene amiretrorepvec 1gallium Ga 68 dotatate 1cabazitaxel 1Radiation 1Proton Magnetic Resonance Spectroscopy 1Procarbazine 1OKN 007 1Nivolumab 1Magnetic Resonance Imaging 1Isotretinoin 1Irinotecan 1Gadolinium DTPA 1Filgrastim 1Equipment and Supplies 1DNA 1Carboplatin 1Biopsy 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Oligodendroglioma × vocimagene amiretrorepvec × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡